SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP

Company

Kyverna Therapeutics, Inc.

Filed

May 3, 2024

Accession Number

0001999371-24-005643

A Schedule 13D is filed when an investor acquires more than 5% of a company's shares with an intent to influence control. Learn more about SC 13D filings →